Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
From MaRDI portal
Publication:3013989
DOI10.1111/j.1541-0420.2010.01471.xzbMath1217.62160arXiv1108.1223OpenAlexW2161784456WikidataQ35797245 ScholiaQ35797245MaRDI QIDQ3013989
Publication date: 19 July 2011
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1108.1223
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Generalized linear models (logistic models) (62J12) Medical applications (general) (92C50) Sequential statistical design (62L05)
Related Items (5)
Optimal sequential designs in phase I studies ⋮ A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ A new characterization of Elfving's method for high dimensional computation ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
Cites Work
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Penalized optimal designs for dose-finding
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Optimal designs for a class of nonlinear regression models
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response
- Adaptive designs for dose-finding based on efficacy-toxicity response
- Bayesian Optimal Designs for Phase I Clinical Trials
- Coherence principles in dose-finding studies
This page was built for publication: Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
